A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-11-04

Study Completion Date

2026-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluate the safety and pharmacodynamics of multiple doses of ARCT-810 in adolescent and adult participants with OTC deficiency.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects

NCT04416126

Ornithine Transcarbamylase Deficiency

COMPLETED PHASE1

Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency

NCT04442347

Ornithine Transcarbamylase Deficiency

COMPLETED PHASE1

Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810

NCT05526066

Ornithine Transcarbamylase Deficiency OTC Deficiency OTCD

TERMINATED PHASE2

Safety, Tolerability and PK/PD Evaluation of Intravenous Administration of MRT5201 in Patients With OTC Deficiency

NCT03767270

Ornithine Transcarbamylase Deficiency

WITHDRAWN PHASE1/PHASE2

A Clinical Study to Measure the Effect of OP-101 After Being Administered Subcutaneous in Healthy Volunteers

NCT04321980

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This a Phase 2a, open-label study of ARCT-810 in participants 12 years of age and older living with OTC deficiency. After a diet stabilization period of at least 4 weeks, all participants will be enrolled to receive ARCT-810 every two weeks, for up to five doses, at one of three dose levels. Clinic visits will occur during screening and at Days 1, 15, 29, 36, 43, 57, 60, 71, and 85. During the study, participants will remain on their current clinical management for OTC deficiency. Dose escalation or cohort expansion may occur following completion of three participants at each dose level.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

OTC Deficiency Ornithine Transcarbamylase Deficiency OTCD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SEQUENTIAL

All participants will receive 5 doses of Study Drug via intravenous infusion at one of the three dose levels. Dose levels will be enrolled sequentially.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ARCT-810

Participants will receive up to 5 IV infusions of ARCT-810 administered at 14-day intervals.

Group Type EXPERIMENTAL

ARCT-810

Intervention Type BIOLOGICAL

ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) messenger RNA (mRNA) formulated in a lipid nanoparticle (LNP).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ARCT-810

ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) messenger RNA (mRNA) formulated in a lipid nanoparticle (LNP).

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Willingness and ability to comply with all the protocol requirements, complete all study visits and sign informed consent.
2. Males and Females aged ≥12 years, at Screening.
3. Documented clinical diagnosis of OTC deficiency.
4. History of symptomatic hyperammonemia or elevated plasma ammonia or glutamine with clinical stability for at least 1 month prior to Screening.
5. Medically managed for OTC deficiency and receiving a stable protein-restricted diet, dietary supplements, and/or ammonia scavenger regimen (if applicable) for at least 28 days.
6. Good general health with no clinically significant abnormal findings that would interfere with study procedures (including plasma ammonia within participant's historical range).
7. Must be willing to adhere to contraception guidelines.

Exclusion Criteria

1. Uncontrolled hypertension.
2. Symptoms of infection for at least 7 days prior to dosing.
3. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated.
4. History of any OTC gene therapy, or history of liver-derived stem cell therapy in the past 2 years.
5. History of any organ transplant.
6. History of severe allergic reaction to a liposomal or PEG-containing product.
7. History of congenital or acquired cardiac disorders.
8. Abuse of medications, illicit drugs or alcohol.
9. Blood donation of 50 to 499 mL within 30 days of screening or of \>499 mL within 60 days of screening.
10. Clinically significant laboratory abnormalities on screening labs including INR \>1.5, eGFR\< 60 mL/min/1.73m2 or positive test results for HIV, HBV, or HCV.
11. Inadequately controlled diabetes.
12. Clinically significant anemia.
13. Changes in maintenance therapies for OTC deficiency with 28 days prior to dosing.
14. Medical history requiring continuous or intermittent systemic corticosteroid administration.
15. Receipt of inhibitors of urea synthesis or drugs that significantly affect renal clearance.
16. Recent treatment with another investigational drug, biological agent, or device.
17. Treatment with any oligonucleotide (siRNA or mRNA) within 6 months prior to screening. COVID-19 vaccines are not exclusionary.
18. Involved in study conduct or an immediate family member of an individual involved in the study.
19. Participated in another dosing cohort of the study.
20. Any other conditions, in the opinion of the investigator, that would interfere with participation.

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No